Product Description: SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162)[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Lyon RP, et al., SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Mol Cancer Ther. 2023 Dec 1;22(12):1444-1453.
Molecular Weight: N/A
Compound Purity: 99.68
Research Area: Cancer
Target: Antibody-Drug Conjugates (ADCs);Integrin